<DOC>
	<DOCNO>NCT02042326</DOCNO>
	<brief_summary>The aim study evaluate efficacy safety sirolimus ( oral form ) , decrease volume symptom due superficial arteriovenous malformation ( AVM ) . Sirolimus property reduce activity immune system ( immunosuppressant ) , fight proliferation cancer cell ( anti- tumor ) also reduce proliferation blood vessel ( anti -vascular ) . Sirolimus primarily use transplant patient prevent organ transplant rejection . Many animal laboratory study carry demonstrate particular activity sirolimus vessel . It anti- vascular effect could help treat arteriovenous malformation .</brief_summary>
	<brief_title>Prospective Evaluation Efficacy Sirolimus ( Rapamune® ) Treatment Severe Arteriovenous Malformations</brief_title>
	<detailed_description>Anti-proliferative anti-angiogenic property Sirolimus ( Rapamycin® ) basis rationale use treatment arteriovenous malformation , pathophysiology remain poorly understood . The interest class drug inhibition mTOR ( mammalian target rapamycin ) may also block growth / angiogenic factor ( VEGF ) involve development AVM . More specifically anti-VEGF drug potential .</detailed_description>
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Arteriovenous Malformations</mesh_term>
	<mesh_term>Hemangioma</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patients ( adult , adolescent child older 2 year ) , arteriovenous malformation stage II + III IV ( accord Schöbinger 's classification ) : active quiescent , mark hemorrhagic phenomenon . Patients ( parent minor ) must sign consent form establish clear information risk expect benefit study . Patients ( major minor childbearing age ) must effective contraception study period continue 12 week end treatment Negative pregnancy blood test woman childbearing age . Chronic acquire immunosuppression : patient transplant organ receive hematopoietic stem cell patient congenital immunodeficiency Patients implant chronic active infection associate hepatitis B , hepatitis C HIV Pregnant nursing woman . Allergy macrolides Allergy peanut soya Hypersensitivity `` Sirolimus `` excipients investigational product Contraindications perform MRI Leukopenia 1 000 /mm3 Thrombocytopenia low 80,000 /mm3 Anemia Hb &lt; 9 g/dl Elevated transaminase &gt; 2.5 N History cancer less two year inclusion Surgery old 2 month inclusion Active infection ( viral bacterial ) date inclusion Hypercholesterolemia &gt; 7 mmol / l despite appropriate medical treatment Hyperlipidemia &gt; 2 mmol / l despite appropriate medical treatment Uncontrolled diabetes Patients unable follow clinical study Major guardianship , person deprive liberty</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Arteriovenous Malformations</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>Maxillofacial Surgery</keyword>
</DOC>